Department of Orthopaedics and Traumatology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.
Comput Math Methods Med. 2022 Jul 6;2022:2368564. doi: 10.1155/2022/2368564. eCollection 2022.
Bisphosphonate is currently considered one of the drugs for the first-line treatment of osteoporosis because of its ability to inhibit bone resorption, but the molecular mechanism of its effect on osteocyte proliferation and bone formation of diabetic osteoporosis is still unclear.
To confirm the potential effect on of bisphosphonate on osteocyte proliferation and bone formation in patients having diabetic osteoporosis (DO).
Sixty DO patients admitted to our hospital from February 2019 to April 2021 were randomly selected and divided into the bisphosphonate group and the control group. The total incidence, incidence of hip fracture, efficacy, bone mineral density, osteocalcin, pain score, osteocyte proliferation, bone formation index, serum calcium, and phosphorus contents were compared between two groups.
The curative effect of bisphosphonic acid group was better than that of control group, and the difference was statistically significant ( < 0.05). Compared with the control group, the bone mineral density and osteocalcin in the bisphosphonic acid group were significantly improved after treatment, and the pain score in the bisphosphonic acid group was significantly lower than that in the control group ( < 0.05). After intervention treatment, the OD and PINP values in the bisphosphonate group were significantly different from those in the control group ( < 0.05). After treatment, the contents of serum calcium and phosphorus in the bisphosphonic acid group were significantly higher than those in the control group ( < 0.05). The incidence of hip fracture, spinal fracture, and other fractures in the bisphosphonic acid group was significantly lower than that in the control group ( < 0.05).
The treatment of DO with bisphosphonate is capability of effectively improving bone cell proliferation and bone formation, further alleviating clinical symptoms and promoting the improvement of the disease.
双膦酸盐目前被认为是治疗骨质疏松症的一线药物之一，因为它能够抑制骨吸收，但它对糖尿病性骨质疏松症患者成骨细胞增殖和骨形成的作用的分子机制尚不清楚。
证实双膦酸盐对糖尿病性骨质疏松症（DO）患者成骨细胞增殖和骨形成的潜在作用。
2019 年 2 月至 2021 年 4 月，我院随机选取 60 例 DO 患者，分为双膦酸盐组和对照组。比较两组总有效率、髋部骨折发生率、疗效、骨密度、骨钙素、疼痛评分、成骨细胞增殖、骨形成指数、血清钙磷含量。
双膦酸盐组的疗效优于对照组，差异有统计学意义（<0.05）。与对照组相比，双膦酸盐组治疗后骨密度和骨钙素明显改善，疼痛评分明显低于对照组（<0.05）。干预治疗后，双膦酸盐组的 OD 和 PINP 值与对照组差异有统计学意义（<0.05）。治疗后，双膦酸盐组血清钙、磷含量明显高于对照组（<0.05）。双膦酸盐组髋部骨折、脊柱骨折等骨折发生率明显低于对照组（<0.05）。
双膦酸盐治疗 DO 能有效改善骨细胞增殖和骨形成，进一步缓解临床症状，促进病情改善。
